Continuing our series, Dr Andrew Whittamore debunks some common myths about asthma – and explains some less well-known facts ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody ...

Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

Crooks advises that asthma, which is one of the most common health conditions, can develop over the course of someone's life, ...

This week Bobbi Conner talks with Dr. Kelli Williams about common asthma triggers in children in springtime. Dr. Williams is ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Among patients with mild-persistent asthma with high SABA use, increased adherence to ICS decreased the proportion of patients with at least 1 exacerbation. Patients with mild asthma have a high level ...

Inflammatory markers play a pivotal role in phenotyping asthma, assessing risks, and tailoring personalised therapeutic strategies, particularly in asthma associated with allergic sensitisation ...